Venture capitalist Nisa Leung has called for Mainland China and Hong Kong to relax their biotechnology listing regulations and lower thresholds for takeovers of listed firms. This appeal comes as foreign investors are showing renewed interest in China's healthcare sector, which Leung argues could be stifled by current IPO bottlenecks and stringent takeover rules. Her comments were made during an interview at the annual meetings of the National Committee of the Chinese People’s Political Consultative Conference and the National People’s Congress.

Leung highlighted the importance of biomedicine alongside artificial intelligence in the context of Premier Li Qiang's government work report. This indicates a strategic focus on the biopharmaceutical industry as a means to advance healthcare outcomes and stimulate economic growth. She urged that easing regulations would not only facilitate access for startups but also enhance China's competitiveness in the global biotechnology landscape.

With the government's continued push towards innovation and sustainable healthcare, the proposed regulatory changes could represent a significant opportunity for foreign investment. By aligning policies to support biotech firms, China and Hong Kong could potentially transform their markets, attract vital investments, and drive forward advancements in medical technology and pharmaceutical development, thereby impacting the overall healthcare system positively.